Aristo Bio-Tech & Lifescience share price & results
- Mar 2026
- Mar 2026
Vadodara (Gujarat)-based agrochemical manufacturer of insecticides, herbicides, fungicides and plant growth regulators, sold across India and exported to 15 countries.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 107 | +2.9% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 8.0 | +6.9 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 3.0 | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | +5.8 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | 1.38 | −0.2 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | −15.3 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance −33.8% 1Y
1Y: ₹130 on 24 Oct 2025 → ₹86. High ₹135 (3 Nov 2025), low ₹75 (30 Mar 2026).
- Previous close
- ₹86
- Market cap
- ₹60 Cr
- 52-week range
- ₹75 – ₹135
- One year
- −33.85%
- Price to earnings (FY ending Mar 2026)
- 8.50×
- Return on equity (FY ending Mar 2026)
- 16.87%
Overview
- Symbol
- NSE:ARISTO
- Sector
- Chemicals
- Industry
- Commodities
- Exchange
- NSE
- Currency
- INR
What Aristo Bio-Tech & Lifescience Ltd does
Based on the company's own presentations, annual report and earnings calls.
Aristo Bio-Tech and Lifescience manufactures, formulates, packages and job-works a range of agrochemicals — insecticides, herbicides, fungicides, plant growth regulators and other pesticides — at its works in Manjusar, Taluka Savli, Vadodara, Gujarat. The company holds 257 products registered with the Central Insecticides Board & Registration Committee (CIB&RC) for manufacture and sale. Products are sold directly to customers and also produced on a job-work basis, supplied across 20 Indian states and exported to 15 countries.
Segments
- Agrochemicals (Crop Protection)
- Products registered with CIB&RC
- 257
- Domestic states served
- 20 states
- Export countries
- 15 countries
- Manufacturing facility
- 1 (Manjusar, Vadodara, Gujarat)
- Permanent employees
- 66 (as on Mar 31, 2025)
- In-house quality control lab testing methods
- HPLC, UV Spectrograph, GC
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
| Line item | Sept 2022 | Mar 2023 | Sept 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 89 | 133 | 112 | 214 | 104 | 256 | 107 |
| Expenses | 124 | 85 | 128 | 109 | 206 | 103 | 249 | 99 |
| Operating profit | 5 | 4 | 5 | 3 | 8 | 1 | 8 | 8 |
| Operating margin | 3.9% | 4.1% | 4.0% | 2.9% | 3.8% | 1.1% | 3.1% | 8.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 1 | 4 | 2 | 6 | -1 | 6 | 4 |
| Tax rate | 28.0% | 13.0% | 28.0% | 27.0% | 25.0% | −18.0% | 25.0% | 27.0% |
| Net profit | 3 | 1 | 3 | 1 | 5 | 0 | 4 | 3 |
| EPS (₹ per share) | 3.80 | 1.47 | 3.78 | 1.94 | 6.68 | -0.72 | 6.13 | 4.42 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 5 | 7 | 7 | 7 | 7 | 7 |
| Reserves | 10 | 23 | 27 | 31 | 35 | 37 |
| Borrowings | 25 | 22 | 21 | 22 | 35 | 35 |
| Other liabilities | 37 | 47 | 73 | 81 | 174 | 76 |
| Total liabilities | 77 | 100 | 127 | 141 | 250 | 155 |
| Fixed assets | 14 | 16 | 22 | 24 | 24 | 24 |
| Capital work in progress | 0 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 63 | 83 | 106 | 117 | 226 | 131 |
| Total assets | 77 | 100 | 127 | 141 | 250 | 155 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 2 | 7 | -3 | 8 | 10 | 9 |
| Cash from investing | -2 | -3 | -4 | -7 | -5 | -3 |
| Cash from financing | -1 | -3 | 8 | -2 | -4 | -4 |
| Net cash flow | 0 | 0 | 1 | -1 | 0 | 2 |
| Free cash flow | 0 | 4 | -7 | 1 | 5 | 6 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 72 | 73 | 75 | 86 | 65 | 55 |
| Inventory days | 78 | 60 | 57 | 65 | 59 | 70 |
| Days payable | 93 | 87 | 85 | 112 | 97 | 78 |
| Cash conversion cycle | 56 | 46 | 48 | 38 | 26 | 47 |
| Working capital days | 28 | 25 | 36 | 31 | 22 | 24 |
| Return on capital employed | 11.0% | 12.0% | 16.0% | 13.0% | 13.0% | 20.0% |
| Dividend payout | 0.0% | 0.0% | 5.0% | 7.0% | 10.0% | 6.0% |
Ownership
Who owns it
Promoters hold 73.42% as of Mar 2026.
- Promoters 73.42%
- Public 26.58%
Who is on the register
Named in the Mar 2026 filing
Every holder of Aristo Bio-Tech & Lifescience Ltd above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| 33.54% | unchanged | |
| 10.58% | unchanged | |
| 9.18% | unchanged | |
| 7.56% | unchanged | |
| 7.05% | unchanged | |
| 3.67% | unchanged | |
| 3.13% | unchanged | |
| 2.35% | unchanged | |
| 1.84% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Aristo Bio-Tech & Lifescience Ltd
Free account: one company. Everything above stays public.
Write why you follow Aristo Bio-Tech & Lifescience Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Chemicals companies
Learn to analyse Aristo Bio-Tech & Lifescience Ltd
Guides on how to read this kind of business and the numbers that matter.